Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Vascular ; 29(2): 220-227, 2021 Apr.
Article in English | MEDLINE | ID: mdl-32691699

ABSTRACT

BACKGROUND: The world is witnessing an unprecedented crisis with Coronavirus disease 2019 (COVID-19). It is important to accurately analyze the available evidence to provide correct clinical guidance for optimal patient care. We aim to discuss current clinical evidence regarding chloroquine, hydroxychloroquine, azithromycin, remdesivir, and the cardiovascular burden of COVID-19. METHODS: A literature review was performed using PubMed and Google Scholar. Additional clinical trials were identified through the "TrialsTracker" project. RESULTS: We found conflicting evidence of chloroquine, hydroxychloroquine plus azithromycin, and remdesivir in COVID-19 despite promising early reports of in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Some of the current studies have demonstrated adverse drug reactions to chloroquine and hydroxychloroquine + azithromycin. Widespread systemic inflammation and procoagulant/hypercoagulable state, including thrombotic microangiopathy, endothelial dysfunction, bleeding disorder, and thrombosis are increasingly being witnessed in COVID-19. Evidence of cardiac injury and stroke is mostly reported in hospitalized patients; however, large specialized studies that focus on cardiac or neuropathology are lacking. DISCUSSION: There is no convincing clinical evidence of chloroquine, hydroxychloroquine with or without azithromycin, and remdesivir use in COVID-19. As evidence of systemic inflammation is rapidly unfolding, there is a dire need to maximize our resources to find the best possible solutions to the current crisis while conclusive evidence from clinical trials emerges.


Subject(s)
Adenosine Monophosphate/analogs & derivatives , Alanine/analogs & derivatives , Azithromycin/pharmacology , COVID-19 Drug Treatment , Cardiovascular Diseases , Chemically-Induced Disorders , Chloroquine/pharmacology , Adenosine Monophosphate/pharmacology , Alanine/pharmacology , Antiviral Agents/pharmacology , COVID-19/epidemiology , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/prevention & control , Chemically-Induced Disorders/etiology , Chemically-Induced Disorders/prevention & control , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/methods , Humans , SARS-CoV-2
2.
J Am Coll Nutr ; 39(2): 94-102, 2020 02.
Article in English | MEDLINE | ID: mdl-32027241

ABSTRACT

Due to their genomic variants, some individuals are more highly affected by toxicants than others. Toxicant metabolizing and activating variants have been linked with a wide variety of health issues including an increased risk of miscarriages, birth defects, Alzheimer's, benzene toxicity, mercury toxicity and cancer. The study of genomics allows a clinician to identify pathways that are less effective and then gives the clinician the opportunity to counsel their patients about diet, supplements and lifestyle modifications that can improve the function of these pathways or compensate to some extent for their deficits. This article will review a few of these critical pathways relating to phase I and phase 2 detox such as GSTP1, GPX1, GSTT1 deletions, PON1 and some of the CYP 450 system as examples of how an individual's genomic vulnerabilities to toxicants can be addressed by upregulating or downregulating specific pathways via genomically targeted use of foods, supplements and lifestyle changes.


Subject(s)
Chemically-Induced Disorders/genetics , Environmental Exposure/adverse effects , Environmental Pollutants/toxicity , Inactivation, Metabolic/genetics , Nutrition Therapy , Benzene/toxicity , Chemically-Induced Disorders/prevention & control , Chemically-Induced Disorders/therapy , Cytochrome P-450 Enzyme System/genetics , Genetic Predisposition to Disease , Glutathione/metabolism , Glutathione Transferase/genetics , Humans , Mercury/toxicity , Mutation , Pesticides/toxicity , Precision Medicine , Reactive Oxygen Species
3.
Vestn Otorinolaringol ; 83(2): 46-50, 2018.
Article in Russian | MEDLINE | ID: mdl-29697655

ABSTRACT

Undesirable effects of the application of the intransal vasoconstricting medications are a frequent occurrence in the pediatric practice. The objective of the present study was to evaluate the role of the intranasal vasoconstricting medications in the structure of the means and methods currently available for the treatment of toxicological pathologies based at a multi-field clinical hospital. The retrospective analysis of the medical histories of the patients admitted to the toxicological department and annual reports for the period from 2015 to 2016 was undertaken. The study has demonstrated that intoxication associated with the use of the intranasal vasoconstricting medications was the most common cause of hospitalization of the children in the toxicological departments. Intoxication of this origin accounted for 15-20% of the total number of toxicological pathologies among the children. The cases of intoxication are most frequently documented in the group of children at the age between 1 and 3 years. The risk of the undesirable serious complications is especially high after the application of naphazoline-based intranasal vasoconstricting medications (71.7-77.4% of all the cases of intoxication with these products). It is concluded that the use of intranasal vasoconstricting medications in the pediatric practice should be carried out under the strict control, with the naphazoline-based preparations being totally excluded from the application.


Subject(s)
Chemically-Induced Disorders , Naphazoline , Nasal Decongestants , Nasal Obstruction/drug therapy , Administration, Intranasal/methods , Chemically-Induced Disorders/diagnosis , Chemically-Induced Disorders/etiology , Chemically-Induced Disorders/prevention & control , Child, Preschool , Female , Humans , Infant , Male , Naphazoline/administration & dosage , Naphazoline/adverse effects , Nasal Decongestants/administration & dosage , Nasal Decongestants/adverse effects , Nasal Obstruction/epidemiology , Retrospective Studies , Risk Assessment , Russia/epidemiology
5.
Acta Medica (Hradec Kralove) ; 60(4): 140-145, 2017.
Article in English | MEDLINE | ID: mdl-29716679

ABSTRACT

AIM: The influence of the dose on the ability of promising newly prepared reversible inhibitor of acetylcholinesterase (6-chlorotacrine) to increase the resistance of mice against soman and the efficacy of antidotal treatment of soman-poisoned mice was evaluated. METHODS: The evaluation of the effect of pharmacological pretreatment is based on the identification of changes of soman-induced toxicity that was evaluated by the assessment of its LD50 value and its 95% confidence limit using probit-logarithmical analysis of death occurring within 24 hrs after administration of soman. RESULTS: The dose of 6-chlorotacrine significantly influences the prophylactic efficacy of 6-chlorotacrine. Its highest dose was only able to significantly protect mice against acute toxicity of soman and increase the efficacy of antidotal treatment (atropine in combination with the oxime HI-6) of soman-poisoned mice. In addition, the highest dose of 6-chlorotacrine was significantly more effective to protect mice from soman poisoning than its lowest dose. CONCLUSION: These findings demonstrate the important influence of the dose of 6-chlorotacine on its prophylactic efficacy in the case of pharmacological pretreatment of soman poisoning in mice.


Subject(s)
Chemically-Induced Disorders/prevention & control , Pre-Exposure Prophylaxis/methods , Soman/poisoning , Tacrine/analogs & derivatives , Animals , Antidotes/pharmacology , Cholinesterase Inhibitors/poisoning , Cholinesterase Reactivators/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Mice , Tacrine/pharmacology
6.
Environ Sci Pollut Res Int ; 23(24): 25280-25287, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27687764

ABSTRACT

Aluminum is ingested through foods, water, air, and even drugs. Its intake is potentiated further through foods and tea prepared in aluminum utensils and Al salt added in the drinking water for removal of suspended impurities and also fluoride in the affected areas. The ameliorating role of a blue green alga Spirulina is well documented to various pollutants in the animal models. We, therefore, examined its protective role (230 mg/kg body weight) on the hematology of male Swiss albino mice treated with aluminum (sub-acute = 78.4 mg/kg body weight for 7 days, sub-chronic = 7.8 mg/kg body weight for 90 days) and aluminum fluoride (sub-acute = 103 mg/kg body weight, sub-chronic = 21 mg/kg body weight), along with their recovery after 90 days of sub-chronic exposure. This study revealed significant reduction in the values of RBC (5-18 %), Hb (15-17 %), PCV (8-14 %), and platelets (26-36 %), and increase in WBC (54-124 %) in the treated mice, particularly after sub-acute exposure. Aluminum fluoride was comparatively more toxic than aluminum. Further, Spirulina supplement not only alleviated toxicity of test chemicals in Swiss albino mice but also led to their better recovery after withdrawal.


Subject(s)
Aluminum Compounds/toxicity , Aluminum/toxicity , Blood/drug effects , Chemically-Induced Disorders/prevention & control , Fluorides/toxicity , Spirulina , Animals , Dietary Supplements , Male , Mice , Phosphates , Random Allocation , Toxicity Tests, Subacute , Toxicity Tests, Subchronic
8.
Rev. esp. anestesiol. reanim ; 63(6): 353-356, jun.-jul. 2016. ilus
Article in English | IBECS | ID: ibc-153077

ABSTRACT

Neurotoxicity caused by cefepime may occur predominantly in patients with impaired renal function. A case of a cefepime-induced non-convulsive status epilepticus (NCSE) is presented. A 65-year-old woman suffered a severe NCSE due to cefepime in the presence of acute renal failure, requiring coma induction with sodium thiopental. A serious interaction between valproic acid (VPA) and meropenem was also produced after changing cefepime to meropenem. Continuous veno-venous haemofiltration was employed to improve cefepime clearance, and the patient progressively regained her previous mental condition. In conclusion, the cefepime dose must be adjusted according to renal function in order to avoid toxicity in patients with renal failure. Electroencephalogram should be considered in cases of acute confusional state in patients receiving cefepime, to achieve early detection of NCSE. Continuous renal replacement therapy may be successfully employed in severe cases in order to accelerate cefepime removal. Likewise, meropenem should not be used concomitantly with VPA (AU)


La neurotoxicidad por cefepime puede producirse principalmente en pacientes con insuficiencia renal. Presentamos un caso de status epiléptico no convulsivo producido por cefepime. Una mujer de 65 años con fracaso renal agudo en tratamiento con cefepime sufrió un episodio grave de status epiléptico no convulsivo que requirió inducción de coma barbitúrico con tiopental sódico. Tras el cambio de cefepime a meropenem se produjo también una interacción grave entre meropenem y ácido valproico. Se utilizó hemofiltración venovenosa continua para acelerar el aclaramiento de cefepime y la paciente recuperó progresivamente su situación neurológica previa. En conclusión, la dosis de cefepime debe ser ajustada a la función renal para evitar toxicidad en pacientes con insuficiencia renal. Debería considerarse la utilización del electroencefalograma en casos de estado confusional agudo en pacientes en tratamiento con cefepime para un diagnóstico precoz del status epiléptico no convulsivo. La terapia continua de reemplazo renal puede ser empleada en casos graves para acelerar la eliminación de cefepime. Además el meropenem no debe de utilizarse concomitantemente con el ácido valproico (AU)


Subject(s)
Humans , Female , Middle Aged , Epilepsy/chemically induced , Epilepsy/complications , Thiopental/therapeutic use , Drug-Related Side Effects and Adverse Reactions/complications , Cephalosporins/adverse effects , Cephalosporins/therapeutic use , Chemically-Induced Disorders/complications , Chemically-Induced Disorders/drug therapy , Hemofiltration/adverse effects , Hemofiltration/trends , Chemically-Induced Disorders/prevention & control , Chemically-Induced Disorders/therapy
10.
Exp Toxicol Pathol ; 66(4): 179-85, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24503513

ABSTRACT

Zearalenone (ZEA) is a mycotoxin commonly found as a contaminant in cereals. ZEA toxicity targets mainly the reproductive system, and oxidative stress plays an etiological role in its toxic effects. Therefore, the present study aimed to investigate the effect of lycopene, a potent carotenoid antioxidant, on markers of oxidative stress in liver, kidney and testes, and on reproductive, hematological and histopathological parameters after ZEA administration. Adult Swiss albino male mice received lycopene (20mg/kg, p.o.) for ten days before a single oral administration of ZEA (40mg/kg, p.o.), and 48h thereafter tissues (liver, kidney, testes and blood) were collected for biochemical, hematological and histological analyses. Lycopene prevented ZEA-induced changes in hematological parameters (increased number of leukocytes, segmented neutrophils, sticks, eosinophils and monocytes and decreased number of red blood cells (RBC), number of lymphocytes and platelets). Moreover, lycopene prevented the reduction in the number and motility of spermatozoa and the testicular tissue damage induced by ZEA. In addition, lycopene prevented the decrease in glutathione-S-transferase activity in kidney and testes and increased glutathione-S-transferase activity per se in the liver, kidneys and testes as well as superoxide dismutase activity in the liver. In summary, lycopene was able to prevent ZEA-induced acute toxic effects in male mice, suggesting that this antioxidant carotenoid may represent a promising prophylactic strategy against ZEA toxicity.


Subject(s)
Antioxidants/therapeutic use , Carotenoids/therapeutic use , Chemically-Induced Disorders , Oxidative Stress/drug effects , Reproduction/drug effects , Zearalenone/toxicity , Animals , Antioxidants/administration & dosage , Blood Cell Count , Carotenoids/administration & dosage , Chemically-Induced Disorders/blood , Chemically-Induced Disorders/pathology , Chemically-Induced Disorders/prevention & control , Erythrocytes/cytology , Erythrocytes/drug effects , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Leukocytes/cytology , Leukocytes/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , Lycopene , Male , Mice , Sperm Motility/drug effects , Spermatozoa/drug effects , Spermatozoa/pathology , Testis/drug effects , Testis/metabolism , Testis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...